Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ACUMEN PHARMACEUTICALS, INC.

(ABOS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
16.03(c) 15.95(c) 15.33(c) 16.18(c) 16.23(c) Last
184 332 334 962 491 538 405 200 1 542 878 Volume
-5.71% -0.50% -3.89% +5.54% +0.31% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -78,0 M - -
Net cash position 2021 225 M - -
P/E ratio 2021 -6,76x
Yield 2021 -
Sales 2022 0,66 M - -
Net income 2022 -41,3 M - -
Net cash position 2022 219 M - -
P/E ratio 2022 -18,7x
Yield 2022 -
Capitalization 657 M 657 M -
EV / Sales 2021 -
EV / Sales 2022 666x
Nbr of Employees 7
Free-Float 88,7%
More Financials
Company
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on advancing a targeted immunotherapy drug candidate, ACU193, and establishing proof of mechanism in early AD patients. The Company's ACU193 is a humanized monoclonal antibody that selectively... 
More about the company
All news about ACUMEN PHARMACEUTICALS, INC.
08/31ACUMEN PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements an..
AQ
08/16ACUMEN PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condi..
AQ
08/16ACUMEN PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Fi..
AQ
08/16ACUMEN PHARMACEUTICALS : Reports Financial Results for Second Quarter 2021 and B..
PU
08/16ACUMEN PHARMACEUTICALS : Reports Financial Results foráSecond Quarter 2021 and B..
AQ
08/16Acumen Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Secon..
CI
07/26ACUMEN PHARMACEUTICALS : Credit Suisse Starts Acumen Pharmaceuticals at Outperfo..
MT
07/26ACUMEN PHARMACEUTICALS : Stifel Initiates Acumen Pharmaceuticals at Buy Rating W..
MT
07/26ACUMEN PHARMACEUTICALS : UBS Starts Acumen Pharmaceuticals at Buy With $27 Price..
MT
07/26ACUMEN PHARMACEUTICALS : BofA Securities Starts Acumen Pharmaceuticals at Neutra..
MT
07/07ACUMEN PHARMACEUTICALS, INC. : Amendments to Articles of Inc. or Bylaws; Change ..
AQ
07/01SECTOR UPDATE : Health Care Stocks Post Solid Gains Thursday
MT
07/01ACUMEN PHARMACEUTICALS : Rises 34% Midday After IPO
MT
07/01ACUMEN PHARMACEUTICALS : Prices Upsized IPO at $16/Share, Expects $160 Million G..
MT
06/30Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public Offering
GL
More news
News in other languages on ACUMEN PHARMACEUTICALS, INC.

- No features available -

More news
Analyst Recommendations on ACUMEN PHARMACEUTICALS, INC.
More recommendations
Chart ACUMEN PHARMACEUTICALS, INC.
Duration : Period :
Acumen Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 16,23 $
Average target price 25,00 $
Spread / Average Target 54,0%
EPS Revisions
Managers and Directors
Daniel J. O'Connell President, Chief Executive Officer & Director
W. Matthew Zuga Chief Financial & Business Officer
Eric Siemers Chief Medical Officer
Russell Barton Chief Operating Officer
Jeffrey L. Ives Director
Sector and Competitors
1st jan.Capi. (M$)
ACUMEN PHARMACEUTICALS, INC.0.00%657
MODERNA, INC.311.65%173 588
LONZA GROUP AG32.35%60 074
IQVIA HOLDINGS INC.43.07%49 116
CELLTRION, INC.-23.26%31 904
SEAGEN INC.-10.81%28 420